Pharmaceutical R&D Pipeline News
Company Analysis - Death of the megadeal
The changing face of the pharmaceutical industry
The merger and acquisition (M&A) landscape of the pharma industry has always been a vital indicator of growth for the business, and is often punctuated by huge ‘megadeals’ which can affect the entire industry.
However, a change in this trend appears to be underway and, looking at the industry as a whole, it seems to be a symptom of a major upheaval taking place in the industry at the moment, in which the original megadeal is no longer a viable path to growth.
Looking back at the M&A trends in 2007, there was a significant increase in the value of activity that took place. The total value of M&A deals was US$79.5bn, a massive 43% increase from 2006’s total of US$55.7bn, and yet there were at most only three that could be considered large and none whatsoever that could qualify as a megadeal. This apparent discrepancy is a reflection of the new way of doing business – big companies making strategic yet still relatively small-scale M&A to bolster their pipelines in key cutting-edge areas.
read full 'Death of the megadeal' company analysis article>>
Latest R&D News
Our news is available via RSS feed. If you are new to RSS news read about how to use it.
-
Cimzia approved in the US for moderate-to-severe Crohn's disease
Mon, 28 Apr 2008 11:48:42 GMT
UCB has announced that the US FDA has approved Cimzia (certolizumab pegol), the first and only PEGylated anti-TNFalpha antibody for use in Crohn's disease... more -
Perampanel development for Parkinson's disease terminated at Phase III
Thu, 17 Apr 2008 15:33:32 GMT
Perampanel (E-2007), Eisai's non-competitive AMPA-type glutamate receptor antagonist, has been discontinued for the treatment of Parkinson's disease... more
Mergers, Acquistions & Joint Ventures
- Abraxis BioScience has acquired Shimoda Biotech.
New Drug Targets
Newly identified drug protein targets.







